Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects

Silvia Cerri, Rosaria Greco, Giovanna Levandis, Cristina Ghezzi, Antonina Stefania Mangione, Marie Therese Fuzzati-Armentero, Arianna Bonizzi, Maria Antonietta Avanzini, Rita Maccario, Fabio Blandini

Research output: Contribution to journalArticle

Abstract

Mesenchymal stemcells (MSCs) have been proposed as a potential therapeutic tool for Parkinson’s disease (PD) and systemic administration of these cells has been tested in preclinical and clinical studies. However, no information on survival and actual capacity of MSCs to reach the brain has been provided. In this study,weevaluatedhoming of intraarterially infused ratMSCs (rMSCs) in thebrain of rats bearing a 6-hydroxydopamine (6-OHDA)-induced lesion of the nigrostriatal tract, to establishwhether the toxininduced damage is sufficient to grant MSC passage across the blood-brain barrier (BBB) or if a transient BBBdisruptionisnecessary.The rMSCdistributioninperipheralorgans and theeffects of cell infusionon neurodegenerative process andmotor deficitswere also investigated. rMSCswere infused 14 days after 6-OHDA injection. A hyperosmolar solution of mannitol was used to transiently permeabilize the BBB. Behavioralimpairmentwas assessedbyadjusting steptestandresponsetoapomorphine.Animalswere sacrificed 7 and 28 days after cell infusion. Our work shows that appreciable delivery of rMSCs to the brainof6-OHDA-lesionedanimalscanbeobtainedonlyaftermannitol pretreatment.Anotablepercentage of infused cells accumulated in peripheral organs. Infusion of rMSCs did notmodify the progression of 6-OHDA-induced damage or themotor impairment at the stepping test, but induced progressive normalization of the pathological response (contralateral turning) to apomorphine administration. These findings suggest thatmany aspects should be further investigated before considering any translation of MSC systemic administration into the clinical setting for PD treatment.

Original languageEnglish
Pages (from-to)1073-1085
Number of pages13
JournalStem cells translational medicine
Volume4
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Oxidopamine
Neuroprotective Agents
Mesenchymal Stromal Cells
Parkinson Disease
Animal Models
Blood-Brain Barrier
Apomorphine
Mannitol
Injections
Brain
Therapeutics

Keywords

  • Behavioral analyses
  • Intracarotid infusion
  • Mannitol
  • Mesenchymal stem cells
  • Neuroprotection
  • Parkinson’s disease

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects. / Cerri, Silvia; Greco, Rosaria; Levandis, Giovanna; Ghezzi, Cristina; Mangione, Antonina Stefania; Fuzzati-Armentero, Marie Therese; Bonizzi, Arianna; Avanzini, Maria Antonietta; Maccario, Rita; Blandini, Fabio.

In: Stem cells translational medicine, Vol. 4, No. 9, 01.09.2015, p. 1073-1085.

Research output: Contribution to journalArticle

Cerri, Silvia ; Greco, Rosaria ; Levandis, Giovanna ; Ghezzi, Cristina ; Mangione, Antonina Stefania ; Fuzzati-Armentero, Marie Therese ; Bonizzi, Arianna ; Avanzini, Maria Antonietta ; Maccario, Rita ; Blandini, Fabio. / Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects. In: Stem cells translational medicine. 2015 ; Vol. 4, No. 9. pp. 1073-1085.
@article{c65b17ed05254ea0be4262ce580c25af,
title = "Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects",
abstract = "Mesenchymal stemcells (MSCs) have been proposed as a potential therapeutic tool for Parkinson’s disease (PD) and systemic administration of these cells has been tested in preclinical and clinical studies. However, no information on survival and actual capacity of MSCs to reach the brain has been provided. In this study,weevaluatedhoming of intraarterially infused ratMSCs (rMSCs) in thebrain of rats bearing a 6-hydroxydopamine (6-OHDA)-induced lesion of the nigrostriatal tract, to establishwhether the toxininduced damage is sufficient to grant MSC passage across the blood-brain barrier (BBB) or if a transient BBBdisruptionisnecessary.The rMSCdistributioninperipheralorgans and theeffects of cell infusionon neurodegenerative process andmotor deficitswere also investigated. rMSCswere infused 14 days after 6-OHDA injection. A hyperosmolar solution of mannitol was used to transiently permeabilize the BBB. Behavioralimpairmentwas assessedbyadjusting steptestandresponsetoapomorphine.Animalswere sacrificed 7 and 28 days after cell infusion. Our work shows that appreciable delivery of rMSCs to the brainof6-OHDA-lesionedanimalscanbeobtainedonlyaftermannitol pretreatment.Anotablepercentage of infused cells accumulated in peripheral organs. Infusion of rMSCs did notmodify the progression of 6-OHDA-induced damage or themotor impairment at the stepping test, but induced progressive normalization of the pathological response (contralateral turning) to apomorphine administration. These findings suggest thatmany aspects should be further investigated before considering any translation of MSC systemic administration into the clinical setting for PD treatment.",
keywords = "Behavioral analyses, Intracarotid infusion, Mannitol, Mesenchymal stem cells, Neuroprotection, Parkinson’s disease",
author = "Silvia Cerri and Rosaria Greco and Giovanna Levandis and Cristina Ghezzi and Mangione, {Antonina Stefania} and Fuzzati-Armentero, {Marie Therese} and Arianna Bonizzi and Avanzini, {Maria Antonietta} and Rita Maccario and Fabio Blandini",
year = "2015",
month = "9",
day = "1",
doi = "10.5966/sctm.2015-0023",
language = "English",
volume = "4",
pages = "1073--1085",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects

AU - Cerri, Silvia

AU - Greco, Rosaria

AU - Levandis, Giovanna

AU - Ghezzi, Cristina

AU - Mangione, Antonina Stefania

AU - Fuzzati-Armentero, Marie Therese

AU - Bonizzi, Arianna

AU - Avanzini, Maria Antonietta

AU - Maccario, Rita

AU - Blandini, Fabio

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Mesenchymal stemcells (MSCs) have been proposed as a potential therapeutic tool for Parkinson’s disease (PD) and systemic administration of these cells has been tested in preclinical and clinical studies. However, no information on survival and actual capacity of MSCs to reach the brain has been provided. In this study,weevaluatedhoming of intraarterially infused ratMSCs (rMSCs) in thebrain of rats bearing a 6-hydroxydopamine (6-OHDA)-induced lesion of the nigrostriatal tract, to establishwhether the toxininduced damage is sufficient to grant MSC passage across the blood-brain barrier (BBB) or if a transient BBBdisruptionisnecessary.The rMSCdistributioninperipheralorgans and theeffects of cell infusionon neurodegenerative process andmotor deficitswere also investigated. rMSCswere infused 14 days after 6-OHDA injection. A hyperosmolar solution of mannitol was used to transiently permeabilize the BBB. Behavioralimpairmentwas assessedbyadjusting steptestandresponsetoapomorphine.Animalswere sacrificed 7 and 28 days after cell infusion. Our work shows that appreciable delivery of rMSCs to the brainof6-OHDA-lesionedanimalscanbeobtainedonlyaftermannitol pretreatment.Anotablepercentage of infused cells accumulated in peripheral organs. Infusion of rMSCs did notmodify the progression of 6-OHDA-induced damage or themotor impairment at the stepping test, but induced progressive normalization of the pathological response (contralateral turning) to apomorphine administration. These findings suggest thatmany aspects should be further investigated before considering any translation of MSC systemic administration into the clinical setting for PD treatment.

AB - Mesenchymal stemcells (MSCs) have been proposed as a potential therapeutic tool for Parkinson’s disease (PD) and systemic administration of these cells has been tested in preclinical and clinical studies. However, no information on survival and actual capacity of MSCs to reach the brain has been provided. In this study,weevaluatedhoming of intraarterially infused ratMSCs (rMSCs) in thebrain of rats bearing a 6-hydroxydopamine (6-OHDA)-induced lesion of the nigrostriatal tract, to establishwhether the toxininduced damage is sufficient to grant MSC passage across the blood-brain barrier (BBB) or if a transient BBBdisruptionisnecessary.The rMSCdistributioninperipheralorgans and theeffects of cell infusionon neurodegenerative process andmotor deficitswere also investigated. rMSCswere infused 14 days after 6-OHDA injection. A hyperosmolar solution of mannitol was used to transiently permeabilize the BBB. Behavioralimpairmentwas assessedbyadjusting steptestandresponsetoapomorphine.Animalswere sacrificed 7 and 28 days after cell infusion. Our work shows that appreciable delivery of rMSCs to the brainof6-OHDA-lesionedanimalscanbeobtainedonlyaftermannitol pretreatment.Anotablepercentage of infused cells accumulated in peripheral organs. Infusion of rMSCs did notmodify the progression of 6-OHDA-induced damage or themotor impairment at the stepping test, but induced progressive normalization of the pathological response (contralateral turning) to apomorphine administration. These findings suggest thatmany aspects should be further investigated before considering any translation of MSC systemic administration into the clinical setting for PD treatment.

KW - Behavioral analyses

KW - Intracarotid infusion

KW - Mannitol

KW - Mesenchymal stem cells

KW - Neuroprotection

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=84940099431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940099431&partnerID=8YFLogxK

U2 - 10.5966/sctm.2015-0023

DO - 10.5966/sctm.2015-0023

M3 - Article

C2 - 26198165

AN - SCOPUS:84940099431

VL - 4

SP - 1073

EP - 1085

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 9

ER -